ISPOR Asia Pacific 2018 Short Course Program

The ISPOR Short Course Program is offered in conjunction with ISPOR meetings around the world as a series of 4 and 8-hour training courses, designed to enhance your knowledge and technique in 7 key topic areas (“Tracks”) related to pharmacoeconomics & outcomes research.  Short courses range in skill level from Introductory to Advanced.

For more information on ISPOR Short Courses, please visit https://www.ispor.org/education/shortcourses.asp or for questions related to this or any other ISPOR Short Course Program, please contact shortcourse@ispor.org.

Click on a tab below to view short courses presented at the ISPOR Asia Pacific 2018 by date, track, level or instructors.
Click on a heading to expand and a title to view the details
Laptop icon Indicates hands-on exercises requiring the use of your personal laptop.
Please note: Separate Short Course registration is required.


Program by Date Program by Track Program by Level Program by Instructor
Saturday, 8 September 2018 - Morning Session
Introduction to Pharmacoeconomics/Health Economics Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Economic Methods
Level: Introductory This course is designed for those with limited experience with pharmacoeconomics (health economics).
Faculty:
David B. Matchar, MD David B. Matchar, MD, Professor & Director, Health Services & Systems Research Programme, Duke-NUS Graduate Medical School, Singapore, Singapore
Hong Li, PhD, MPH Hong Li, PhD, MPH, Lead, Trans-Pacific Outcomes Research LLC, Adjunct Professor, School of Public Health, Shanghai Jiaotong University, Shanghai, China, and Adjunct Associate Professor, School of Pharmacy, Cincinnati University, Cincinnati, OH, USA
Course Description:
This course is designed to teach clinicians and researchers the basics of pharmacoeconomic (health economic) analysis in health care. This course will include the basic theory for determining cost and outcomes, the different types of costs and costing methods. Analysis methods to be discussed include cost-minimization, cost-benefit analysis, cost-utility (cost per QALY), cost-effectiveness, and incremental cost-effectiveness ratios (ICERS). The course will also highlight how analyses are framed, evaluated and reported. Finally, the course will outline challenges and considerations when utilizing pharmacoeconomics as a tool for developing clinical guidelines for health care systems. Applications of Pharmacoeconomics/Health Economics in Asia will also be discussed.
Introduction to Real World Data and Informatics in Health Care Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Observational Data Methods
Level: Introductory This course is designed for those with little experience with data analysis or observation.
Faculty:
Jeff J. Guo, PhD Jeff J. Guo, PhD, Professor, Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati, Cincinnati, OH, USA
Kinwei Arnold Chan, MD, MPH, ScD Kinwei Arnold Chan, MD, MPH, ScD, Director, Department of Medical Research, National Taiwan University Hospital, Director, Health Data Research Center, and Professor, College of Medicine, National Taiwan University, Taipei, Taiwan
Course Description:
This course will discuss issues surrounding health care data and health informatics in Asia, including established data sources such as patient registries and clinical data warehouses, methodologies surrounding data collection and sharing across health systems, data management through established health information systems, electronic health records, and data utilization (analytics), as well as issues of clinical and economic data transferability across jurisdictions. Emerging trends in big data and their future role in Asia will also be introduced.
Elements of Pharmaceutical/Biotech Pricing I Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Introductory This introductory course is designed for those with limited experience in pharmaceutical pricing and reimbursement.
Faculty:
Jack M. Mycka, N/A Jack M. Mycka, N/A, Global President & CEO, Medical Marketing Economics LLC (MME), Montclair, NJ, USA
Manny Papadimitropoulos, MScPhm, PhD Manny Papadimitropoulos, MScPhm, PhD, Health Outcomes Scientific Leader, Latin America, Eli Lilly, and Adjunct Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Shanlian Hu, MD, MSc Shanlian Hu, MD, MSc, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China
Course Description:
This course will give participants a basic understanding of the key terminology and issues involved in pricing decisions and the principles of market access. It covers the tools to document product value, the role of pharmacoeconomics and the differences in payment systems that help pricing decisions. Recent pharmaceutical spending patterns, trends and cost-containment measures will also be discussed, taking into account the wider policy context. The health systems approach in several countries will be presented.
Introduction to Health Technology Assessment Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Introductory This course is suitable for those with little or no experience with HTA.
Faculty:
Uwe Siebert, MD, MPH, MSc, ScD Uwe Siebert, MD, MPH, MSc, ScD, Professor, Department of Public Health, Health Services Research & HTA/ONCOTYROL, Department of Health Policy & Management, Area 4 HTA & Bioinformatics/Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hall i. T., Austria
Yen-Huei (Tony) Tarn, PhD, MS Yen-Huei (Tony) Tarn, PhD, MS, Associate Professor, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan
Course Description:
This course will teach participants about the key principles, elements, methods, and language of health technology assessment (HTA), and provide an overview of basic HTA disciplines including benefit assessment (biostatistics, clinical epidemiology, patient-relevant outcomes, risk-benefit assessment), economic evaluation (costing, cost-effectiveness analysis, pharmacoeconomic modeling, budget impact analysis, resource allocation), and ELSI (ethical, legal and social implications). Participants will also learn to be prepared for discussions between different stakeholders regarding the implementation of HTA in decision making.
NEW! Budget Impact Analysis I: A 6-Step Approach Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Economic Methods
Level: Intermediate This course is designed for those with some experience with pharmacoeconomic analysis.
Faculty:
C. Daniel Mullins, PhD C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA
Jianwei Xuan, MD, PhD Jianwei Xuan, MD, PhD, Professor & Director, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China
Course Description:
This course will describe the methods used to estimate the budget impact of a new health care technology, and will present six basic steps for estimating budget impact: 1) estimating the target population; 2) selecting a time horizon; 3) identifying current and projected treatment mix; 4) estimating current and future drug costs; 5) estimating change in disease-related costs; and 6) estimating and presenting changes in annual budget impact and health outcomes. Both static and dynamic methods for estimating the budget and health impact of adding a new drug to a health plan formulary will be presented. These six steps will be illustrated using actual budget impact models.
NEW! Medical Devices in Asia-Pacific: Regulatory and Reimbursement Issues Register Now
 
Saturday, 8 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate This course is designed for those with limited experience in the area of medical device reimbursement and regulatory issues and covers topics within a global context.
Faculty:
Eugene Salole, PhD, MPH Eugene Salole, PhD, MPH, Principal & CEO, Value-Based Access Pty Ltd, and Conjoint Professor, Faculty of Medicine, UNSW, Sydney, UK
Jack Wong, RPh Jack Wong, RPh, Head, Regulatory Affairs - Asia-Pacific, Baxter Healthcare, Singapore, Singapore
Course Description:
The processes and requirements for regulatory and reimbursement approval of medical devices are decidedly unique compared to pharmaceuticals, given the vast breadth of technologies, the rapid pace of innovation and technology disruption, and complex product life cycles. As patients continue to demand greater access to innovative medical technologies, payers are adapting their requirements for evidence and value demonstration for approval. This course will provide an overview on the key differences between medical devices and drugs with respect to regulatory approval and reimbursement. Current trends within the regulatory environment of Asia-Pacific and globally will be examined, including core evidence requirements. Finally, several case studies will be presented on the market access of innovative medical devices in Asia-Pacific, European and US markets.
Saturday, 8 September 2018 - Afternoon Session
Introduction to Modeling Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Modeling Methods
Level: Introductory This course will introduce pharmacoeconomic modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages with practical application, along with a review of the ISPOR Modeling Good Research Practices.
Faculty:
Shu Chuen Li, MApplSc, MBA, PhD Shu Chuen Li, MApplSc, MBA, PhD, Chair Professor of Pharmacy & Head of Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia
Jipan Xie, MD, PhD Jipan Xie, MD, PhD, Vice President, Analysis Group, Inc., New York, NY, USA
Course Description:
This course will introduce modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages, including a review of the ISPOR Modeling Good Research Practices. Examples will be presented using Microsoft Excel, with add-on simulation software. This course will include practical steps in the selection of models and options in modeling of data inputs.
Cost Effectiveness Analysis Alongside Clinical Trials Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Economic Methods
Level: Intermediate Familiarity with economic evaluations will be helpful.
Faculty:
Chee Jen Chang, PhD Chee Jen Chang, PhD, Director & Professor, Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan
David Bin-Chia Wu, PhD David Bin-Chia Wu, PhD, Assistant Director & Lead Specialist (Economic Modeling), Agency for Care Effectiveness, MOH, Singapore, Singapore
Course Description:
The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and reimbursement requirements of many countries that now consider evidence of economic value along with clinical efficacy. This course will present the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials based on, in part, the Good Research Practices for Cost-Effectiveness Analysis alongside Clinical Trials: The ISPOR RCT-CEA Task Force Reports. Trial design, selecting data elements (measures of cost and outcomes), database design and management, analysis, and reporting of results will be presented. Trials designed to evaluate effectiveness (rather than efficacy) as well as clinical outcome measures will be discussed. How to obtain health resource use and health state utilities directly from study subjects and economic data collection fully integrated into the study will also be discussed. Analyses guided by an analysis plan and hypotheses, an incremental analysis using an intention to treat approach, characterization of uncertainty, and standards for reporting results will be presented. Various case studies will be employed to guide participants through the elements listed above.
Patient-Reported Outcomes Measures (PROMs): Cross-Cultural Development and Validation Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Patient-Reported Outcomes Methods
Level: Introductory This course is designed for those with limited experience with quality of life/PRO studies.
Faculty:
Bruce Crawford, MA, MPH Bruce Crawford, MA, MPH, Vice President, Real World Evidence & Insights, Syneos Health Japan G.K., Tokyo, Japan
Nan Luo, Ph.D. Nan Luo, Ph.D., Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Course Description:
This course will introduce the definitions and concepts, methodologies, and practical methods for measuring patient-reported outcomes will be presented. The value of patient-reported outcomes assessment will be discussed. A strategy to aid in selecting appropriate instruments and the translation processes will be presented with considerations for regional needs. Instrument development and validation will be discussed using practical examples and exercises, including ISPOR Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures.
Retrospective Database Design and Analysis Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Observational Data Methods
Level: Introductory This course is designed for those with little experience with database analysis.
Faculty:
Jeff J. Guo, PhD Jeff J. Guo, PhD, Professor, Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati, Cincinnati, OH, USA
Xin Sun, PhD Xin Sun, PhD, Professor, Chinese Evidence-based Medicine Center, West China Hospital of Sichuan University, Chengdu, China
Course Description:
Retrospective studies require strong principles of epidemiologic study design and complex analytical methods to adjust for bias and confounding. This course will provide an overview of fundamental design strategies, analytic techniques and specific best practices to improve causal inference in studies using retrospective databases. Specific topics to be covered at an introductory level include: measurement of exposure and outcome, causal graphs, new user study design, measures of comorbidity, the use of stratification analysis before multivariable modeling, multivariable regression including Cox proportional hazards survival analysis, model performance and diagnostic testing, propensity scoring, instrumental variable and structural modeling techniques including marginal structural models.
Case Studies in Pharmaceutical / Biotech Pricing II – Advanced Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.
Faculty:
Jack M. Mycka, N/A Jack M. Mycka, N/A, Global President & CEO, Medical Marketing Economics LLC (MME), Montclair, NJ, USA
Manny Papadimitropoulos, MScPhm, PhD Manny Papadimitropoulos, MScPhm, PhD, Health Outcomes Scientific Leader, Latin America, Eli Lilly, and Adjunct Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Shanlian Hu, MD, MSc Shanlian Hu, MD, MSc, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China
Course Description:
Case studies will be employed to lead participants through the key steps of new product pricing, with focus on the need to thoroughly analyze the business environment and its constraints and opportunities, and the need to closely integrate the pricing, reimbursement, and pharmacoeconomic strategy for the new product with the clinical development and marketing strategies. Practical exercises will allow participants to consolidate the concepts delivered in the “Elements” introductory session and expanded here. Areas covered will include the post-launch issues of reimbursement and pricing maintenance as a part of life-cycle management in a global environment.
NEW! Budget Impact Analysis II: Applications & Design Issues Register Now
 
Saturday, 8 September 2018
1:00 PM - 5:00 PM
Room: TBD
Track: Economic Methods
Level: Intermediate This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.
Faculty:
Jianwei Xuan, MD, PhD Jianwei Xuan, MD, PhD, Professor & Director, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China
Yi Han, PhD, MS, MBA Yi Han, PhD, MS, MBA, Executive Vice President, Market Access, HEOR and Advanced Analytics, WPP Health and Wellness/WG Consulting, New York, NY, USA
Course Description:
This course provides an opportunity for participants to engage with concrete applications of the six-step approach for developing budget impact analyses and to participate in hands-on learning with two different budget impact models programmed in Excel. The course will review the basics of budget impact analysis, interpretation of results, critical questions to consider when using a budget impact analysis, and how such analyses are used by payers and other decision makers. The course will cover technical topics such as use of static versus dynamic budget impact models, considerations for budget impact analyses of device and diagnostic technologies, and how to handle important issues such as patient copayments and use of generics. To help participants engage with the course content, the instructors will walk through two different budget impact analyses programmed in Excel (one static and one dynamic), work with participants on hands-on exercises to enhance these models, present conceptual content, and lead discussion on various topics. The instructors will also review good practices for building budget impact models and provide a number of Excel tips. The Excel-based budget impact models used for the course will be provided to participants in advance of the conference.
Sunday, 9 September 2018 - Morning Session
NEW! Applied Modeling Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Modeling Methods
Level: Intermediate This course is suitable for those who are familiar with the various modeling methods.
Prerequisite: Participation in the ISPOR short course “Introduction to Modeling Methods,” or equivalent knowledge, is recommended.
Faculty:
Mark S. Roberts, MD, MPP Mark S. Roberts, MD, MPP, Professor & Chair, Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
David Bin-Chia Wu, PhD David Bin-Chia Wu, PhD, Assistant Director & Lead Specialist (Economic Modeling), Agency for Care Effectiveness, MOH, Singapore, Singapore
Course Description:
This course is an introduction to the use of software for the creation and analysis of cost-effectiveness decision models. Participants will learn how to use software to develop and analyze a simple decision tree, create a cost effectiveness model that incorporates cost and utilities, extend the model to incorporate time-vary events through the application of state-transition (Markov) processes, and conduct one-way, two-way, and probabilistic sensitivity analyses. This course will provide hands-on experience through practical tutorials. All participants must bring a Windows laptop computer with a copy of TreeAge Pro Suite installed and running. You will be provided download and installation instructions when you pre-register for the course.
Statistical Methods in Health Economic Evaluations Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate This course is designed for those with a basic understanding of statistics.
Faculty:
Jalpa A. Doshi, PhD Jalpa A. Doshi, PhD, Associate Professor of Medicine, Economic Evaluations Unit, Center for Evidence-based Practice and Director, Value-Based Insurance Design Initiatives, Center for Health Incentives, University of Pennsylvania, Philiadelphia, PA, USA
Chee Jen Chang, PhD Chee Jen Chang, PhD, Director & Professor, Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan
Course Description:
Adoption and diffusion of new medical treatments depend increasingly on robust analysis of costs and cost-effectiveness (CEA). The source of this evidence often comes from patient-level economic data collected in clinical trials. This course will discuss statistical considerations when dealing with patient-level cost data, including the effect of distributional assumptions, univariate and multivariable analyses of data, sample size and power calculations, and estimation of sampling uncertainty for cost-effectiveness analysis. Examples will be provided to illustrate concepts.
Health-Related Quality of Life (HRQOL) Weights for Economic Evaluations Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Patient Preference Methods
Level: Introductory No prior knowledge of health-related quality of life is assumed.
Faculty:
Alex Z. Fu, PhD Alex Z. Fu, PhD, Associate Professor, Oncology, Georgetown University, Washington, DC, USA
Nan Luo, Ph.D. Nan Luo, Ph.D., Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Course Description:
This course is designed to provide an overview of preference-based health-related quality of life measures to support economic evaluations. The concepts of utility or health-state utility measurement will be introduced, and similarities and differences with profile-based health-related quality of life measurement will be discussed. The course will describe how health-state utility data can be combined with survival to estimate quality-adjusted life years (QALY), which is applied in economic evaluations for valuing treatments or health outcomes. Methods that are used to capture utility values such as standard gamble, time trade-off, and rating scales will be introduced, along with a presentation of the different generic instruments that have been developed for measuring utilities such as the EQ-5D, Health Utilities Index, and SF-6D. Mapping functions (the practice of estimating the target health-state utility as a function of the health outcomes that have been measured in the key clinical studies of effectiveness, using an external dataset) will be described. Finally, we will describe the requirements and preferences of different reimbursement agencies around the world including USA, Europe and Asia. The course will be interactive with break-out sessions and group discussion.
Network Meta-Analysis and Indirect Treatment Comparisons Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Outcomes Research Methods
Level: Intermediate This course is designed for those with some understanding of meta-analysis.
Prerequisite: Participation in the short course “Meta-Analysis and Literature Review in Comparative Effectiveness Research,” or equivalent knowledge, is recommended.
Faculty:
Jeonghoon Ahn, PhD Jeonghoon Ahn, PhD, Associate Professor, Department of Health Convergence, Ewha Womans University, Seoul, Korea, Republic of (South)
Nathorn Chaiyakunapruk, PharmD, PhD Nathorn Chaiyakunapruk, PharmD, PhD, Professor, Discipline of Pharmacy, Monash University Malaysia, Petaling Jaya, Malaysia
Course Description:
When head-to-head randomized controlled trials are absent, network meta-analysis (also commonly referred to as a multiple treatment comparison meta-analysis or mixed treatment meta-analysis) offers a quantitative method of integrating all the data from all the available comparisons while indirect treatment comparisons can be conducted and provides useful evidence. In this course, the fundamentals and concepts of network meta-analysis will be presented. ISPOR Good Research Practices for Conducting and Interpreting Network Meta-Analysis and Indirect Treatment Comparisons will also be presented. Participants will be able to understand the concepts and assumptions of network meta-analysis (indirect and mixed treatment comparisons), such as heterogeneity, transitivity, and consistency, critically analyze the results of network meta-analysis, recognize the statistical models used to explore heterogeneity and inconsistency, and know that WinBUGS and SAS can be used to perform network meta-analysis.
Risk-Sharing/Performance-Based Schemes for Drugs & Medical Devices Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate It will be helpful for individuals to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.
Faculty:
Louis P. Garrison, PhD Louis P. Garrison, PhD, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA
Adrian Towse, MA, MPhil Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
Course Description:
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved. Although these agreements have an intrinsic appeal, there can be substantial barriers to their implementation. Theory and practice, including incentives and barriers, will be analyzed along with several country-specific examples.
NEW! Introduction to Big Data Analysis: Graph Analytics Register Now
 
Sunday, 9 September 2018
8:00 AM - 12:00 PM
Room: TBD
Track: Observational Data Methods
Level: Intermediate
Faculty:
David R. Holmes III, PhD David R. Holmes III, PhD, Director, Biomedical Imaging Resource and Collaborative Scientist, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, USA
Course Description:
Semantic graph databases can change the way that we look at data, and graph analytics yields new insights into existing and soon-to-be collected datasets. This course will address how graph analytics are used to deal with issues of data quality and data completeness, the implications for the confidence in the conclusions drawn from these analyses, and where the challenges still lie in data migration and data quality. Issues related to node-typed, edge-typed, and directed graphs, using the resource description framework (RDF) to describe information in a graph, using SPARQL, and application of inferential rules and ontologies to the dataset will be discussed.
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.